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HepcidinCeruloplasmin plays an essential role in cellular iron efﬂux by oxidizing ferrous iron exported from
ferroportin. Ferroportin is posttranslationally regulated through internalization triggered by hepcidin
binding. Aceruloplasminemia is an autosomal recessive disorder of iron homeostasis resulting from
mutations in the ceruloplasmin gene. The present study investigated the biological effects of glycosylpho-
sphatidylinositol (GPI)-linked ceruloplasmin on the hepcidin-mediated internalization of ferroportin. The
prevention of hepcidin-mediated ferroportin internalization was observed in the glioma cells lines
expressing endogenous ceruloplasmin as well as in the cells transfected with GPI-linked ceruloplasmin
under low levels of hepcidin. A decrease in the extracellular ferrous iron by an iron chelator and incubation
with puriﬁed ceruloplasmin in the culture medium prevented hepcidin-mediated ferroportin internalization,
while the reconstitution of apo-ceruloplasmin was not able to prevent ferroportin internalization. The effect
of ceruloplasmin on the ferroportin stability was impaired due to three distinct properties of the mutant
ceruloplasmin: namely, a decreased ferroxidase activity, the mislocalization in the endoplasmic reticulum,
and the failure of copper incorporation into apo-ceruloplasmin. Patients with aceruloplasminemia exhibited
low serum hepcidin levels and a decreased ferroportin protein expression in the liver. The in vivo ﬁndings
supported the notion that under low levels of hepcidin, mutant ceruloplasmin cannot stabilize ferroportin
because of a loss-of-function in the ferroxidase activity, which has been reported to play an important role in
the stability of ferroportin. The properties of mutant ceruloplasmin regarding the regulation of ferroportin
may therefore provide a therapeutic strategy for aceruloplasminemia patients., Hamamatsu University School
Japan. Tel.: +81 53 435 2261;
).
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In the majority of physiological conditions, the extracellular
transport of iron by ferroportin (Fpn) is regulated by the hepatic
peptide hepcidin in response to inﬂammation and hepatic iron overload
[1]. Hepcidin binds to Fpn, which is present on cell surfaces, and thereby
induces the phosphorylation of two tyrosine residues on an intracellular
loopof Fpn. Thesephosphorylationevents result in the internalization of
the Fpn–hepcidin complex, ubiquitination of Fpn, and lysosomal
degradation of both proteins [2,3]. Fpn transports intracellular ferrous
iron (Fe2+) to transferrin via the oxidization of ferrous iron to ferric iron
(Fe3+) by the multicopper oxidase ceruloplasmin (Cp) [4]. Serum Cp is
primarily synthesized in hepatocytes as the secreted form of Cp (Cp-S).Bioactive Cp is a holo form of Cp (holo-Cp) and six atoms of copper are
incorporated during biosynthesis. The failure to incorporate copper into
Cp results in the secretion of anunstable apo formof Cp (apo-Cp),which
is devoid of any oxidase activity and rapidly degrades in the serum. Cp is
located on the surface of astrocytes in the brain, and the glycosylpho-
sphatidylinositol (GPI)-linked Cp (Cp-GPI) plays a major role in the
mobilization of iron in the central nervous system [5,6].
Aceruloplasminemia is a hereditary iron overload disease caused
by loss-of-function mutations in the Cp gene, resulting in impaired
iron efﬂux from the cells. Affected patients present with hepatic iron
overload, iron-refractory anemia, retinal degeneration, diabetes
mellitus, and neurological symptoms due to parenchymal iron
accumulation [7]. Our previous studies have identiﬁed two biological
properties of mutant Cp that resulted in misfolding and retention in
the endoplasmic reticulum (ER) and interfered with copper incorpo-
ration in the late secretory pathway [8–11]. The present study
identiﬁed a third property of mutant Cp associated with decreased
ferroxidase activity resulting in loss of Fpn stability under low levels of
hepcidin, although the mutant Cp was synthesized and secreted with
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observed in patients with aceruloplasminemia: namely, a decreased
Fpn protein expression in the liver under low serum hepcidin levels.
2. Materials and methods
2.1. Expression plasmids
Human GPI-linked Cp cDNA was cloned into the expression vector
pcDNA3 (Invitrogen, Carlsbad, CA, USA). A plasmid encoding the full-
length human SLC40A1 Fpn gene (IMAGE CLONE ID 5213437) was
purchased from Thermo Scientiﬁc Open Biosystems (Huntsville, AL,
USA). The cDNA was then subcloned into PcDNA6.2/GW/D-TOPO
(Invitrogen) to generate the V5-epitope fusion protein at the C-
terminus, and site-directed mutagenesis was performed using the
QuikChange site-directed mutagenesis kit (Agilent Technologies, La
Jolla, CA, USA) according to the manufacturer's protocol to generate
the Cp-GPI mutants and an Fpn mutant.
2.2. Cell culture and transfection
HeLa cells, C6 cells and U251MG cells were provided by RIKEN BRC
through the National Bio-Resource Project of theMEXT, Japan. The cells
weremaintained inbasalmedia containingDMEMwith10% fetal bovine
serum and were transiently transfected with LipofectAMINE2000
(Invitrogen) according to the manufacturer's instructions. Thereafter,
the immunoﬂuorescent and immunoblotting analyses were performed
as described [8]. In the cells incubated with and without human
hepcidin-25 (Bachem, Bubendorf, Switzerland), the cells were treated
for 4 h in serum-freemedium,OPTI-MEM(Invitrogen)with andwithout
apo-transferrrin or holo-transferrin (AppliChem, Darmstadt, Germany)
or were pretreated for 24 h in 250 μM bathocuproinedisulfonic acid
(BCS; Sigma-Aldrich, St. Louis, MO, USA), 100 μM tetraethylenepenta-
mine (TEPA; Sigma-Aldrich), 600 μM bathophenanthroline disulfate
(BPS), or puriﬁed human ceruloplasmin (Sigma-Aldrich).
2.3. Immunoblot and immunoﬂuorescent analysis
The transfected cells were plated on coverslips, ﬁxed with 4%
paraformaldehyde, and quenched with 1 M ethanolamine. The cells
were permeabilized in 0.1% Triton X-100 and analyzed with a goat
anti-ceruloplasmin antibody (1:200, Bethyl Laboratories, Montgom-
ery, TX, USA), a rabbit anti-V5 antibody (1:250, Kamiya biomedical
company, Seattle, WA, USA), an anti-rabbit IgG Alexa488 secondary
antibody, or an anti-goat IgG Alexa593 secondary antibody (1:1000;
Invitrogen). For the Western blot analyses the cell lysates or liver
homogenateswere immunoblotted as previously described using a goat
anti-ceruloplasmin antibody (1:1000, Bethyl Laboratories), a rabbit
anti-V5 antibody (1:1000, Kamiya biomedical company), a rabbit anti-
ferroportin antibody (1:750, Alpha Diagnostics, San Antonio, TX, USA),
and the anti-rabbit IgG HRP and anti-goat IgG HRP antibodies (1:2000;
Santa-Cruz Biotechnology, Santa Cruz, CA, USA) [8]. A quantiﬁcation
analysis of Fpn localized on the cell surface was performed by
counting the cells expressing Fpn on the cell surface among the
transfected cells in a 0.8 mm2 area of a coverslip using the image J
software program (http://rsbweb.nih.gov/ij/index.html). The anal-
ysis was independently performed three times by two blinded
investigators.
2.4. Oxidase assay
The serum-freemedia fromHeLa cells expressingwild-type or Cp-S
mutants were concentrated and dialyzed, followed by an analysis of
the oxidase activity. A para-phenylenediamine (pPD) oxidase staining
of SDS gels was performed by incubation in 0.1 μM pH 5.7 sodiumacetate at 37 °C as previously described [12]. The ferroxidase assay of
the concentrated media was performed as previously described [13].
2.5. Patients
The clinical features and mutations in the Cp gene of patients with
aceruloplasminemia in the present study have been previously
reported [10,14–16]. Fasting serum samples were obtained from
control subjects or patients who had not received iron chelation
therapy or a phlebotomy, and were stored in−80 °C until the assays
were performed. The serum hepcidin-25 levels were measured using
surface-enhanced laser deposition/ionization time of ﬂight mass
spectrometry-based Protein Chip System array technology (Cipher-
gen Biosystems, Palo Alto, CA, USA) [17]. All patients gave their
written informed consent for this study. The study protocol conﬁrms
to ethical guidelines of the 1975 Declaration of Helsinki as reﬂected by
the approval by the Ethical Committee of The Hamamatsu University
School of Medicine.
2.6. Real-time PCR analysis
The ﬁrst-choice human total RNA survey kit (Applied Biosystems,
Foster City, CA, USA) was used to investigate the RNA levels in
human tissues. Total RNA from the liver biopsy samples of three
control subjects and two patients with aceruloplasminemia who had
not received iron chelation therapy or phlebotomy was extracted
using the MELT Total Nucleic Acid Isolation System (Applied
Biosystems). For the real-time RT-PCR analyses, 2 μg of RNA were
reverse-transcribed using the High Capacity cDNA Archive Kit
(Applied Biosystems). Semiquantitative PCR was used to quantify
the RNA levels of the secreted form of Cp, the GPI-linked form of CP
RNA, SLC40A1 encoding Fpn, and the HAMP gene encoding hepcidin.
RNA expression was calculated using a control mRNA plasmid
standard curve, and was normalized to the GAPDH or B2M
housekeeping gene. TaqMan expression assays for the secreted
form of Cp (Applied Biosystems; Hs00375596_m1), HAMP (Applied
Biosystems; Hs00221783_m1), and SLC40A1 (Hs00205888_m1)
were used for the quantiﬁcation of the transcripts. The primers for
the analyses of RNA speciﬁc for GPI-kinked Cp with a TaqMan assay
were: forward, 5'-AATGGAAACCACTTACACCGTTCTA-3' and reverse,
5'-GATCACATTCCATATTCTCCTGTGA -3'. The results are expressed as
the mean of three independent experiments.
3. Results
3.1. Cp-GPI stabilized cell surface Fpn
The cellularproperty of Cp-GPI associatedwith stability of Fpnon the
cell surface was examined. HeLa cells lacking both endogenous Cp and
Fpn synthesis were chosen for the present study and were used for the
following biological experiments with Cp-GPI mutants. The cells
transfected with Fpn with the V5 immunotag (Fpn-V5) were internal-
ized, thus resulting in the formation of intracellular vesicles following
the treatmentwith 0.15 and 0.5 μMhepcidin for 4 h (Fig. 1A). However,
the internalization of Fpn-V5 after the treatmentwith 0.15 μMhepcidin
was not observed in the cells transfectedwith Cp-GPI. Hepcidin binding
to Fpn induces the phosphorylation of two Y302 and Y303 tyrosine
residues of Fpn, therefore resulting in the internalization of Fpn [3]. The
cells transfected with Fpn-V5 bearing the two Y302F and Y303F
mutations stably expressed Fpn on the cell surface, even after treatment
with hepcidin, thus indicating that the Fpn internalization is caused by
the interaction with hepcidin (Fig. 1A). Human U251MG glioma cells
and rat C6 glioma cells expressed endogenous Cp-GPI. Treatment with
0.15 μMhepcidin in these glioma cells did not result in internalized Fpn.
Although the cells expressing either endogenous or exogenous Cp-GPI
stabilized Fpn following treatment with 0.15 μM hepcidin, the addition
Fig. 1. GPI-linked ceruloplasmin stabilizes cell surface ferroportin. (A) HeLa cells were transiently transfected with plasmids containing Fpn-V5, Fpn-V5 with the Y302F and Y303F
mutations, and Cp-GPI and U251MG and C6 cells were also transfected with Fpn-V5. Sixteen hours post-transfection, the cells were incubated with 0.15 or 0.5 μM human hepcidin-25
and were examined for the cellular localization of Fpn and Cp-GPI by an immunoﬂuorescence analysis. (B) The cells transfected with Fpn-V5 were incubated with 0.15. 0.3 or 0.5 μM
human hepcidin-25 in serum-free media for 4 h, and the cells expressing Fpn localized on the cell surface were quantiﬁed by counting the transfected cells. The results represent the
mean±the standard error from three independent experiments. The statistical data analyses were performed using the Mann–Whitney U-test. *Pb0.01 compared to the cell counts
untreated with hepcidin. (C) The transfected cells were analyzed by a Western blot analysis using an anti-V5 antibody and an anti-actin antibody.
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cells (Fig. 1A). A quantiﬁcation analysis revealed that treatment with
0.5 μMhepcidinwas sufﬁcient to display an inverse correlation between
the concentrationofhepcidin and thenumber of the cells expressing cellsurface Fpn (Fig. 1B). Following treatment with 0.15 μM hepcidin,
approximately 35% of the transfected cells exhibited cell surface Fpn,
while the HeLa cells transfected with Cp-GPI and the C6 and U251MG
glioma cells prevented Fpn internalization (Fig. 1B). However, hepcidin
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the cells expressing Cp-GPI which occurred in a concentration-
dependent manner. A Western blot analysis of Fpn conﬁrmed these
results (Fig. 1C). These ﬁndings showed that hepcidin and Cp-GPI acted
as competitors affecting Fpn internalization, and that Cp-GPI had only a
limited effect on Fpn stability under low hepcidin concentrations.
3.2. Ferroxidase activity of Cp is necessary for cell surface Fpn stability
An immunoblot analysis of cell lysates treatedwith copper chelators
of BCS or TEPA revealed the presence of a 130 kDa band, representing
the apo form of Cp-GPI, and an 80 kDa band, representing the holo-Cp,
therefore suggesting that the copper chelators can reconstitute the apo
form of Cp-GPI without ferroxidase activity (Fig. 2A) as described
previously [8,9]. Incubation of cells transfectedwith Fpn-V5 and Cp-GPIFig. 2. Ferroxidase activity of ceruloplasmin is necessary for cell surface ferroportin stability
copper chelators BCS (250 μM) or TEPA (100 μM) for 24 h. The cells expressing Fpn on the c
examined by a Western blot analysis using an anti-ceruloplasmin antibody. *Pb0.01 versus t
serumwas pretreated with cell culture medium for 24 h, and the cells were transfectedwith F
absence of 0.15 μMhepcidin. The statistical data analyses were performed using the Kruskal–
post hoc test. *Pb0.01 versus the cell counts untreated with hepcidin or treated with cerulop
the presence or absence of 0.15 μMhepcidin. (D) The cells transfected with Fpn-V5were incu
0.15 μM hepcidin. A quantiﬁcation analysis was performed as described in Fig. 1B and cell
untreated with hepcidin. Results represent the mean±the standard errors from three indewith the copper chelators induced Fpn internalization following
hepcidin treatment (Fig. 2A). The addition of bioactive puriﬁed
human Cp prevented hepcidin-mediated Fpn internalization (Fig. 2B).
A quantiﬁcation analysis revealed that incubation with 600 μM of the
impermeable ferrous iron chelator BPS displayed a correlation between
the concentration of BPS and the number of the cells expressing the cell
surface Fpn under treatmentwith 0.15 μMhepcidin (Fig. 2C). Reducing
the extracellular ferrous iron concentration led to the accumulation of
Fpn on the cell surface. The addition of exogenous apo-transferrin or
holo-transferrin in the cells transfected with Fpn-V5 did not prevent
hepcidin-induced Fpn internalization, thus indicating that transferrin
could not be substituted for Cp in stabilizing Fpn (Fig. 2D).
These results indicated that the ferroxidase activity of Cp
promoted low extracellular ferrous iron conditions and stabilized
Fpn to maintain efﬁcient iron transport.. (A) Cells were transfected with Fpn-V5 and pretreated in the presence or absence of
ell surface among the transfected cells were analyzed as described in Fig. 1B and were
he cell counts untreated with hepcidin. (B) Human ceruloplasmin (1 μM) puriﬁed from
pn-V5, quantiﬁed and examined by an immunoﬂuorescence analyses in the presence or
Wallis U test followed by the Mann–Whitney U-test with Bonferroni's correction for the
lasmin. (C) The cells transfected with Fpn-V5 were incubated with 300 or 600 μMBPS in
batedwith 5 or 50 μMapo-transferrin and holo-transferrin in the presence or absence of
s were examined by an immunoﬂuorescence analysis. *Pb0.01 versus the cell counts
pendent experiments.
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The biosynthesis of either wild-type Cp-GPI or seventeen Cp-GPI
mutants, including three novel Y356HG873E andM966Vmutants, was
performed to examine the effects of these residues. The immunoﬂu-
orescence analysis of transfected cellswith orwithout permeabilization
with Triton X-100 revealed that the mutants are either diffusely
localized on the cell surface or reside in the perinuclear compartment
(Fig. 3A). The mutants that trafﬁcked to the perinuclear region
colocalized with the ER resident protein disulﬁde isomerase (data not
shown), indicating that themutants are retained in the ER as previously
described [8,11]. The cells treated without Triton X-100 expressed Cp
on the entire cell surface, therefore suggesting its cell surface
localization. This ﬁnding showed that the Cp-GPI mutants, including
Y356H, G631R, Q692K, R701W, G876A, M966V, and G969S, are
localized on the cell surface, while the I9F, D58H, G176R, P177R,
F198S, W264S, A331D, G606E, and G873E mutants are retained in the
ER. Treatment with 200 μM CuCl2 in the culture media increased the
expression of the holo form of Cp (holo-Cp) [10]. An immunoblot
analysis of cell lysates from M966V, G631R, G969S, and Q692K Cp-GPI
cells revealed themutants to be synthesized as apo-Cp, even though the
transfected cells were incubated in the medium containing excess
CuCl2. This ﬁnding suggested that the mutants had impaired copper
incorporation. Y356H, R701W, and G876A mutants were synthesized
as the apo-Cp and holo-Cp (Fig. 3B). An examination of the biosynthesis
of themutants by an immunoﬂuorescence analysis and an immunoblot
analysis revealed ﬁndings consistent with those observed in other cell
culture systems, including Chinese hamster ovary cells or COS7 cells,
which have no endogenous Cp synthesis (data not shown).
The M966V, G631R, G969S, and Q692K mutants had an impaired
copper incorporation, the P177R and W858X mutants were retained
in the ER as previously described [8,18], and the Y356H, R701W, and
G876A mutants had identical synthesis and trafﬁcking character-
istics to wild-type Cp, but each failed to stabilize Fpn on cell surface
(Fig. 3C). Although the Y356H, R701W, and G876A mutants could
form the holo-Cp, the mutants were unable to prevent the Fpn
internalization. The oxidase activity of the mutants was investigated
because the stability of Fpn was associated with the ferroxidase
activity of wild-type Cp. Although the Y356H, R701W, andG876ACp-S
mutants were present in a ratio of apo-to-holo Cp equivalent to that
observed for wild-type Cp (Fig. 3D), both the pPD oxidase gel staining
(Fig. 3D) and the ferroxidase assay (Fig. 3E) revealeddecreased catalytic
activity of these mutants. These ﬁndings suggested that the mutants
which constitute a holo form of Cp on the cell surface cannot prevent
Fpn internalization because of the inherently impaired oxidase activity.
3.4. Hepatic Fpn levels and serum hepcidin levels decrease in patients
with aceruloplasminemia
The human tissue distribution of RNA expression of Cp-S and Cp-GPI
was examined by a semiquantitative real-time PCRanalysis. The human
genome contains a single gene for Cp, but cells can synthesize either
Cp-S or Cp-GPI. The Cp-GPI is generated by alternative RNA splicing
which occurs downstream of exon 18 and replaces the C-terminal 5
amino acids of the secreted form, and incorporate an alternative 30
aminoacids that signal the addition of theGPI anchor [5]. TheGPI-linked
form of Cp is the major form in the brain, whereas the secreted form of
Cp is predominant in the liver. RNA speciﬁc for Cp-S was mainly
expressed in the liver, while Cp-GPI was expressed in all tissues
including the liver, trachea, heart, and brain (Fig. 4A). The Fpn
expression in patients with aceruloplasminemia was investigated in
the liver, where both Cp-GPI and Cp-S were expressed. An immunoblot
analysis for Fpn revealed low Fpn levels in the liver samples of two
patients (Fig. 4B); however, the RNA levels of the SLC40A1 gene
encoding Fpn were increased in the livers of the patients (Fig. 4C).
Patients exhibited decreased serum hepcidin levels (Table 1) anddecreased RNA levels of the HAMP gene encoding hepcidin (Fig. 4D).
These ﬁndings indicated that the hepatic expression of Fpn was
suppressed in patients with aceruloplasminemia, due to Fpn degrada-
tion rather than decreased Fpn synthesis.
4. Discussion
Cellular iron export requires the concentrated actions of a
ferroxidase known to be the copper-containing protein Cp and a
ferrous iron transporter Fpn, which is regulated by hepcidin. Previous
studies showed that Cp-GPI was essential for the stability of cell
surface Fpn in C6 rat glioma cells with endogenous Cp-GPI, and that
cell surface Fpn is rapidly internalized and ubiquitinated for
degradation by silencing of the endogenous Cp gene [19,20].
However, transfected Fpn is localized on the cell surface in a variety
of cultured cells without endogenous Cp, as observed in the current
study [2,21]. De Domenico et al. [19] speculated that Cp-GPI
expressing cells may have cellular properties recognizing the ferrous
iron-bound form of cell surface Fpn by an E3 ligase speciﬁc to these
cells. The current cell culture model using HeLa cells without
endogenous Cp-GPI and Fpn revealed that either Cp ferroxidase
activity or extracellular chelation of ferrous iron is required for cell
surface Fpn stability, as observed in a previous study using C6 cells
[19]. The stabilization of Fpn mediated by Cp was observed in the
human glioma U251MG cells expressing endogenous Cp as well as in
C6 cells, but this observation was restricted by the treatment under
low hepcidin concentrations, namely as low as 0.15 μM. Incubation
with hepcidin concentrations over 0.15 μM caused internalization of
Fpn in HeLa cells transfected with Cp-GPI, U251MG cells and C6 cells.
Therefore, the present study demonstrated that hepcidin and Cp-GPI
acted as competitors affecting Fpn internalization. A dose-responsive
counteracting effect of hepcidin on Fpn stability mediated by Cp
revealed hepcidin to be a primary negative regulator of Fpn
expression, while Cp was a limited positive regulator effecting Fpn
stability under low hepcidin conditions.
The biological effects of Cpmutants on Fpn stabilitywere investigated
using the culture model. More than thirty aceruloplasminemia-causing
mutations have been identiﬁed [7]. This biosynthesis study of sixteen
missense mutants revealed three distinct pathological mechanisms. As
previously seen with the I9F, G176R, and P177R mutants, the D58H,
F198S, W264S, A331D, G606E, and G873E mutants were retained in the
ER [8,11]. Thismechanismpresumably results from themisfolding that is
common to many inherited diseases [22]. We previously reported that
the analysis of the amino acid sequence of Cp revealed a novel G(FLI) (LI)
GP repeat motif, which is believed to affect folding during the early
secretory pathway [9]. The G873E, G176R, and P177Rmutants affect the
conserved repeated G (FLI) (LI) GP motif, which is consistent with this
hypothesis, whereas the G876A mutant was not retained in the ER. The
mutants located beside thismotif are speculated to have othermolecular
mechanisms in cellular trafﬁcking of Cp. A second formof theM966Vand
Q692Kmutants identiﬁed in this studywas synthesizedandwas secreted
with normal kinetics, but failed to incorporate copper during the late
secretory pathway, resulting in the constitution of apo-Cp as has been
previously reported for the G631R andG969Smutants [9,10]. The G631R
and G969S mutations are located in the nearby type I copper-binding
His637 and His975 sites, respectively. Q692K and M966V mutations are
also located near the type I copper-binding sites of M690 and His975,
respectively. A site-directed mutagenesis analysis of the type I copper
binding site indicated that these mutants failed to incorporate copper
into the apo-Cp [9]. These biochemical studies demonstrated that the
type I copper binding site did not affect either protein folding for
intracellular trafﬁcking from the ER to the Golgi body or the subsequent
protein secretion from the cell. The copper binding site may play an
essential role in the protein structure for copper incorporation into the
apo-Cp. The Y356H, R701W, and G876Amutants reconstituted both apo
and holo proteins and were localized to the cell surface. However, these
Fig. 3. Biosynthetic analysis of ceruloplasmin mutants. (A) The cells transfected with sixteen Cp-GPI mutants were examined by an immunoﬂuorescence analysis using an
anti-ceruloplasmin antibody with or without 0.1% Triton X-100 permeabilization. (B) The cells transfected with the Cp-GPI mutants incubated with 200 μM CuCl2 in the
culture medium were examined by an immunoblot analysis. (C) The cells expressing Fpn localized on the cell surface were analyzed as described in Fig. 1B. *Pb0.01,
**Pb0.05 versus the cell counts untreated with hepcidin. (D) Concentrated medium from the cells transfected with wild-type and mutant Cp-S constructs were analyzed by
a Western blot analysis or were incubated with para-phenylenediamine (pPD) for a pPD oxidase assay. (E) The concentrated medium from the cells transfected with Cp-S
wild type or mutants was analyzed with a ferroxidase assay. *Pb0.01 versus the wild-type medium. Results represent the mean±the standard errors from three
independent experiments.
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Table 1
Clinical data and the serum hepcidin levels in patients with aceruloplasminemia.
Patient Sex Age Genotype TS Fe Ferritin Hepcidin-25
1 M 60 W858X 8.0 22 1,936 6.9
2 F 58 W858X 9.8 25 1,610 8.8
3 F 55 c.2482delG 13.3 33 1,180 10.3
4 M 58 c.2602delG 10.7 27 1,775 7.4
5 M 60 c.607insA 6.5 18 2,465 4.8
6 F 70 G969S 13.2 33 980 15.0
7 F 66 c.1286insTACAC 10.6 29 1,875 4.5
Normal values for adults are as follows: hepcidin-25 (AU); 14.8–27.0, ferritin (μg/L);
39.4–320 for males, 3.6–114 for females, iron (μg/dL); 54–200 for males, 48–154 for
females. TS indicates transferrin saturation (%); 25–47 for males, 18–40 for females.
Fig. 4. Hepatic expression of Fpn proteins and its transcription in the patients with
aceruloplasminemia. (A) The RNA levels of the GPI-linked form and secreted form of
ceruloplasmin in different human tissue specimens. A semiquantitative real-time PCR
analysis was performed using human total RNA from several tissue specimens.
Ceruloplasmin expression was calculated using a control mRNA plasmid standard
curve, then was normalized to GAPDH expression. (B) An immunoblot analysis using
ceruloplasmin (Cp), ferroportin (Fpn), and beta-2-microglobulin (B2M) antibodies
was performed using liver biopsy samples obtained from three control subjects and
two patients with aceruloplasminemia (patients 5 and 7 in Table 1). The RNA levels of
(C) SLC40A1 encoding ferroportin and (D) HAMP encoding hepcidin in the liver were
examined by a semiquantitative real-time PCR analysis. SLC40A1 and HAMP
expression levels were calculated using a control mRNA plasmid standard curve,
and were then normalized to B2M expression. The results represent the mean±the
standard errors from three independent measurements.
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impaired the ferroxidaseactivitywhich is required for Fpnstability. These
ﬁndings therefore revealed the third biological property of the Cp
mutant, which is distinct from the impairment of cellular trafﬁcking in
the ER and copper incorporation in the late secretary pathway. These
mutants may alter the iron binding site or the tri-nuclear copper cluster,
which are essential for oxidase activity. Itwill be necessary to analyze the
crystal structure of mutant Cp proteins, which will provide insight into
the mechanism of ferroxidase activity.
The current biological analyses in vitro suggested that theCpmutants
impaired Fpn stability. However, Fpnandhepcidin expression in vivohas
not yet been investigated in patients with aceruloplasminemia. Thepresent study in patients with aceruloplasminemia revealed that serum
hepcidin levels and HAMP RNA levels in the liver are lower than in
control subjects. There may be an inverse correlation between serum
hepcidin levels and serum ferritin levels, suggesting that an inappropri-
ately low transcriptional level of hepcidin exists for the degree of
systemic iron stores. The low hepcidin levels may contribute to the
pathological mechanism of aceruloplasminemia, because low serum
hepcidin levels induce increased iron absorption in the intestine where
theCphomologhephaestin retains ferroxidase activity that is involved in
basolateral intestinal iron transport [23]. Chronic iron overload in vivo
promotes the hemojuvelin (HJV)-dependent bone morphogenetic
proteins (BMPs)/SMAD4 signaling, resulting in increased hepcidin
gene transcription [24,25]. The iron-dependent regulation of hepcidin
in hepatocytes is regulated by competitive interactions with cell surface
multi-protein complexes including HJV, HFE, transferrin receptor 1
(TFR1), transferrin receptor 2 (TFR2), and diferric transferrin [26]. In
hereditary haemochromatosis, the levels of plasma andurinary hepcidin
and hepatic HAMP expression are inappropriately low for the degree of
systemic iron stores due tomutations in the genes encodingHFE,HAMP,
HJV, and TFR2 [27–29]. Transferrin saturation in patients with acerulo-
plasminemia has been observed to decrease because Cp mutants fail to
oxidize ferrous iron into ferric iron, therefore resulting in less
incorporation of ferric iron into transferrin. Preliminary data regarding
hepcidin levels in patients with aceruloplasminemia suggested that a
decrease in diferric transferrin may impair interactions of the multi-
protein complexes, resulting in decreased hepcidin synthesis. Future
investigation of hepatic expression of the BMPs, SMAD4, HJV, HFE, TFR1,
and TFR2 in aceruloplasminemia will elucidate the iron-dependent
regulation of hepcidin expression.
The liver is the predominant source of serum Cp, and extrahepatic
Cp expression has been shown in several tissues, including the retina
and brain [30]. The present study revealed that two forms of Cp-S and
Cp-GPI were expressed in the liver. The hepatic expression of Fpn
proteins and its transcription was analyzed to evaluate the stability of
Fpn in vivo. In patients with aceruloplasminemia, the hepatic Fpn
protein levels were decreased despite the presence of high SLC40A1
RNA levels. Decreased Fpn protein levels in the liver may be due to
degradation due to the absence of Cp rather than decreased synthesis of
Fpn at the transcriptional level. In patients with aceruloplasminemia,
hepatic Fpnproteinwas expressedat low levels, even though the serum
hepcidin levels were low. These in vivo ﬁndings were consistent with
our ﬁnding in a cell culture study, which showed that under low
hepcidin levels mutant Cp-GPIs that impaired the ferroxidase activity
could not stabilize Fpnon cell surface, whilewild-type Cp-GPI inhibited
Fpn internalization by competing with hepcidin. Therefore, the
degradation of Fpn observed in aceruloplasminemia patients may
result from a loss of function in Fpn stability caused bymutations in Cp.
5. Conclusions
The results of the present study suggested that Cp-GPI mutants fail
to stabilize the cell surface localization of Fpn in vitro and in vivo. The
975S. Kono et al. / Biochimica et Biophysica Acta 1802 (2010) 968–975biosynthetic analysis of Cp mutants revealed a novel biological
property of impaired ferroxidase activity, resulting in a loss of Fpn
stability. This observation suggests that iron chelation therapy for
aceruloplasminemia patients harboring these mutations may de-
crease the levels of extracellular ferrous iron, thereby preventing the
degradation of cell surface Fpn.
Financial disclosure
This study was not sponsored by any other entities. All authors
report that no conﬂicts of interest or ﬁnancial relationships exist.
Acknowledgments
We thank Prof. Jonathan D. Gitlin (Vanderbilt University School of
Medicine) for providing the cDNA of GPI-linked ceruloplasmin. Satoshi
Kono and Kenichi Yoshida contributed equally to this manuscript.
References
[1] T. Ganz, E. Nemeth, Iron imports. IV. Hepcidin and regulation of body iron
metabolism, Am. J. Physiol. Gastrointest. Liver Physiol. 290 (2006) G199–G203.
[2] E. Nemeth, M.S. Tuttle, J. Powelson, M.B. Vaughn, A. Donovan, D.M. Ward, T. Ganz,
J. Kaplan, Hepcidin regulates cellular iron efﬂux by binding to ferroportin and
inducing its internalization, Science 306 (2004) 2090–2093.
[3] I. De Domenico, D.M. Ward, C. Langelier, M.B. Vaughn, E. Nemeth, W.I. Sundquist,
T. Ganz, G. Musci, J. Kaplan, The molecular mechanism of hepcidin-mediated
ferroportin down-regulation, Mol. Biol. Cell 18 (2007) 2569–2578.
[4] N.E. Hellman, J.D. Gitlin, Ceruloplasmin metabolism and function, Annu. Rev. Nutr.
22 (2002) 439–458.
[5] B.N. Patel, R.J. Dunn, S. David, Alternative RNA splicing generates a
glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian
brain, J. Biol. Chem. 275 (2000) 4305–4310.
[6] S.Y. Jeong, S. David, Glycosylphosphatidylinositol-anchored ceruloplasmin is
required for iron efﬂux from cells in the central nervous system, J. Biol. Chem. 278
(2003) 27144–27148.
[7] S. Kono, H. Miyajima, Molecular and pathological basis of aceruloplasminemia,
Biol. Res. 39 (2006) 15–23.
[8] N.E. Hellman, S. Kono, H. Miyajima, J.D. Gitlin, Biochemical analysis of a missense
mutation in aceruloplasminemia, J. Biol. Chem. 277 (2002) 1375–1380.
[9] N.E. Hellman, S. Kono, G.M. Mancini, A.J. Hoogeboom, G.J. De Jong, J.D. Gitlin,
Mechanisms of copper incorporation into human ceruloplasmin, J. Biol. Chem. 277
(2002) 46632–46638.
[10] S. Kono, H. Suzuki, K. Takahashi, Y. Takahashi, K. Shirakawa, Y. Murakawa,
S. Yamaguchi, H. Miyajima, Hepatic iron overload associated with a decreased
serum ceruloplasmin level in a novel clinical type of aceruloplasminemia,
Gastroenterology 131 (2006) 240–245.
[11] S. Kono, H. Suzuki, T. Oda, H. Miyajima, Y. Takahashi, K. Shirakawa, K. Ishikawa,
M. Kitagawa, Biochemical features of ceruloplasmin gene mutations linked to
aceruloplasminemia, Neuromolecular Med. 8 (2006) 361–374.[12] C.C. Askwith, J. Kaplan, Site-directed mutagenesis of the yeast multicopper
oxidase Fet3p, J. Biol. Chem. 273 (1998) 22415–22419.
[13] O. Erel, Automated measurement of serum ferroxidase activity, Clin. Chem. 44
(1998) 2313–2319.
[14] Z.L. Harris, Y. Takahashi, H. Miyajima, M. Serizawa, R.T. MacGillivray, J.D. Gitlin,
Aceruloplasminemia:molecular characterizationof this disorder of ironmetabolism,
Proc. Natl Acad. Sci. USA 92 (1995) 2539–2543.
[15] Y. Takahashi, H. Miyajima, S. Shirabe, S. Nagataki, A. Suenaga, J.D. Gitlin,
Characterization of a nonsense mutation in the ceruloplasmin gene resulting in
diabetes and neurodegenerative disease, Hum. Mol. Genet. 5 (1996) 81–84.
[16] N. Okamoto, S. Wada, T. Oga, Y. Kawabata, Y. Baba, D. Habu, Z. Takeda, Y. Wada,
Hereditary ceruloplasmin deﬁciency with hemosiderosis, Hum. Genet. 97 (1996)
755–758.
[17] N. Tomosugi, H. Kawabata, R. Wakatabe, M. Higuchi, H. Yamaya, H. Umehara,
I. Ishikawa, Detection of serum hepcidin in renal failure and inﬂammation by
using ProteinChip System, Blood 108 (2006) 1381–1387.
[18] S. Kono, H. Suzuki, T. Oda, K. Shirakawa, Y. Takahashi, M. Kitagawa, H. Miyajima,
Cys-881 is essential for the trafﬁcking and secretion of truncated mutant
ceruloplasmin in aceruloplasminemia, J. Hepatol. 47 (2007) 844–850.
[19] I. De Domenico, D.M. Ward, M.C. di Patti, S.Y. Jeong, S. David, G. Musci, J. Kaplan,
Ferroxidase activity is required for the stability of cell surface ferroportin in cells
expressing GPI-ceruloplasmin, EMBO J. 26 (2007) 2823–2831.
[20] M.C. di Patti, N. Maio, G. Rizzo, G. De Francesco, T. Persichini, M. Colasanti,
F. Polticelli, G. Musci, Dominant mutants of ceruloplasmin impair the copper
loading machinery in aceruloplasminemia, J. Biol. Chem. 284 (2009) 4545–4554.
[21] I. De Domenico, D.M. Ward, E. Nemeth, M.B. Vaughn, G. Musci, T. Ganz, J. Kaplan,
The molecular basis of ferroportin-linked hemochromatosis, Proc. Natl Acad. Sci.
USA 102 (2005) 8955–8960.
[22] J.H. Lin, P. Walter, T.S. Yen, Endoplasmic reticulum stress in disease pathogenesis,
Annu. Rev. Pathol. 3 (2008) 399–425.
[23] G.J. Anderson, D.M. Frazer, A.T. McKie, S.J. Wilkins, C.D. Vulpe, The expression and
regulation of the iron transport molecules hephaestin and IREG1: implications for
the control of iron export from the small intestine, Cell Biochem. Biophys. 36
(2002) 137–146.
[24] J.L. Babitt, F.W. Huang, D.M. Wrighting, Y. Xia, Y. Sidis, T.A. Samad, J.A. Campagna,
R.T. Chung, A.L. Schneyer, C.J. Woolf, N.C. Andrews, H.Y. Lin, Bone morphogenetic
protein signaling by hemojuvelin regulates hepcidin expression, Nat. Genet. 38
(2006) 531–539.
[25] L. Lin, E.V. Valore, E. Nemeth, J.B. Goodnough, V. Gabayan, T. Ganz, Iron transferrin
regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin
and BMP2/4, Blood 110 (2007) 2182–2189.
[26] I. De Domenico, D. McVey Ward, J. Kaplan, Regulation of iron acquisition and
storage: consequences for iron-linked disorders, Nat. Rev. Mol. Cell Biol. 9 (2008)
72–81.
[27] K.R. Bridle, D.M. Frazer, S.J. Wilkins, J.L. Dixon, D.M. Purdie, D.H. Crawford,
V.N. Subramaniam, L.W. Powell, G.J. Anderson, G.A. Ramm, Disrupted hepcidin
regulation inHFE-associated haemochromatosis and the liver as a regulator of body
iron homoeostasis, Lancet 361 (2003) 669–673.
[28] E. Nemeth, A. Roetto, G. Garozzo, T. Ganz, C. Camaschella, Hepcidin is decreased in
TFR2 hemochromatosis, Blood 105 (2005) 1803–1806.
[29] G. Papanikolaou,M. Tzilianos, J.I. Christakis, D. Bogdanos, K. Tsimirika, J.MacFarlane,
Y.P. Goldberg, N. Sakellaropoulos, T. Ganz, E. Nemeth, Hepcidin in iron overload
disorders, Blood 105 (2005) 4103–4105.
[30] L.W. Klomp, J.D. Gitlin, Expression of the ceruloplasmin gene in the human retina
and brain: implications for a pathogenic model in aceruloplasminemia, Hum. Mol.
Genet. 5 (1996) 1989–1996.
